Pharmaceutical firms face many challenges in bringing their products through clinical trials — from enrollment delays to data quality issues — and every advantage can make a difference. In image analysis, sponsors can gain a critical advantage by leveraging artificial intelligence/machine learning.
Artifical intelligence (AI) and machine learning (ML) allow rapid and efficient assessment of images and can aid in more accurate identification, classification and measurement of specimens. Leveraging ML in a clinical trial will:
- Boost speed: AI allows automatic interpretation of images, which shave weeks off the timeline for patient enrollment
- Improve quality of images and interpretations: AI can detect medically relevant findings, as well as poor quality medical images, improving the integrity of clinical trial results and patient health.
- Ensure consistency: Without AI, sponsors see up to 40% variability on different radiologists’ readings of scans. Variability with ML is significantly better.